Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC) by unknown
Dubin et al. BMC Nephrology 2013, 14:229
http://www.biomedcentral.com/1471-2369/14/229RESEARCH ARTICLE Open AccessPredictors of high sensitivity cardiac troponin T in
chronic kidney disease patients: a cross-sectional
study in the chronic renal insufficiency
cohort (CRIC)
Ruth F Dubin1*, Yongmei Li1, Jiang He2, Bernard G Jaar3, Radhakrishna Kallem4, James P Lash5, Gail Makos6,
Sylvia E Rosas4, Elsayed Z Soliman7, Ray R Townsend4, Wei Yang8, Alan S Go9, Martin Keane4,
Christopher deFilippi10, Rakesh Mishra1, Myles Wolf11, Michael G Shlipak1 and The CRIC Study InvestigatorsAbstract
Background: Cardiac troponin T is independently associated with cardiovascular events and mortality in patients
with chronic kidney disease (CKD). Serum levels of high sensitivity cardiac troponin T (hs-TnT) reflect subclinical
myocardial injury in ambulatory patients. We sought to determine the distribution and predictors of hs-TnT in CKD
patients without overt cardiovascular disease (CVD).
Methods: We studied 2464 participants within the multi-ethnic Chronic Renal Insufficiency Cohort (CRIC) who did
not have self-reported CVD. We considered renal and non-renal factors as potential determinants of hs-TnT,
including demographics, comorbidities, left ventricular (LV) mass, serologic factors, estimated glomerular filtration
rate (eGFR) and albumin to creatinine ratio.
Results: Hs-TnT was detectable in 81% of subjects, and the median (IQR) hs-TnT was 9.4 pg/ml (4.3-18.3). Analysis
was performed using Tobit regression, adjusting for renal and non-renal factors. After adjustment, lower eGFR was
associated with higher expected hs-TnT; participants with eGFR < 30 ml/min/1.73 m2 had 3-fold higher expected
hs-TnT compared to subjects with eGFR > 60. Older age, male gender, black race, LV mass, diabetes and higher
blood pressure all had strong, independent associations with higher expected hs-TnT.
Conclusions: Knowledge of the determinants of hs-TnT in this cohort may guide further research on the pathology
of heart disease in patients with CKD and help to stratify sub-groups of CKD patients at higher cardiovascular risk.
Keywords: Troponin T, Chronic kidney disease, Cardiovascular diseaseBackground
Studies have shown that lower estimated glomerular fil-
tration (eGFR) and higher albumin to creatine ratio
(ACR) are strong, independent risk factors for incident
heart failure [1-3]. However, how chronic kidney disease
(CKD) leads to heart failure is not fully understood; specif-
ically, we lack information on which biological mediators
of CKD initiate myocardial injury and whether certain
subgroups of patients with CKD are more susceptible to* Correspondence: ruth.dubin@ucsf.edu
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reproduction in any medium, provided the ormyocardial injury. High sensitivity cardiac troponin T (hs-
TnT) independently predicts cardiovascular mortality in
populations with or without cardiac disease [4-6], and pre-
dicts cardiovascular events [7,8] and all-cause mortality
[9] in patients with CKD and end-stage renal disease [10].
Since the highly sensitive assay detects much lower levels
of myocardial injury than prior assays, it may be useful for
studying the earliest stages of heart disease in subjects
with CKD. Our group has shown that hs-TnT is inde-
pendently associated with left ventricular hypertrophy
(LVH) in participants of the CRIC cohort who do not have
self-reported cardiovascular disease (CVD) [11]. Add-
itional culprits in the CKD milieu thought to contribute totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Distribution of high sensitivity troponin t among
chronic renal insufficiency cohort participants without self-
reported cardiovascular disease. Legend: Hs-TnT was detectable
in 81% of subjects; median (IQR) of hs-TnT was 9.4 pg/ml (4.3-18.3). All
hs-TnT values greater than 100 pg/ml were truncated in one bar at 100.
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and deranged mineral metabolism. Whether these factors
are associated with subclinical myocardial injury (as mea-
sured by hs-TnT) in a CKD cohort without overt CVD
has not been previously studied.
We sought to examine renal and non-renal predictors
of subclinical myocardial injury using hs-TnT in subjects
without self-reported CVD in the Chronic Renal Insuffi-
ciency Cohort (CRIC). First, we hypothesized that lower
estimated glomerular filtration rate (eGFR) and higher
urine albumin-creatinine ratio (ACR) would be inde-
pendently associated with higher hs-TnT concentration.
Second, we hypothesized that elevated fibroblast growth
factor 23 (FGF-23) concentrations, hyperphosphatemia,
and anemia would be associated with higher hs-TnT in-
dependently of eGFR.
Methods
The Chronic Renal Insufficiency Cohort (CRIC) Study was
designed to investigate risk factors for progression of CKD,
cardiovascular disease and overall mortality in persons
with CKD. Participants were recruited between June 2003
and March 2007 at seven centers (Ann Arbor, Michigan;
Baltimore, Maryland; Chicago, Illinois; Cleveland, Ohio;
New Orleans, Louisiana; Philadelphia, Pennsylvania; and
Oakland, California). Investigators recruited 3939 racially
and ethnically diverse individuals between the ages of 21
to 74 years with eGFR between 20 and 70 ml/min/1.73m2
by simplified MDRD equation [12]. Exclusion criteria were
as follows: polycystic kidney disease, use of immunosup-
pression within the last 6 months, institutionalization, in-
ability to consent, enrollment in other studies, pregnancy,
New York Heart Association class III to IV heart failure,
HIV, cirrhosis, myeloma, renal cancer, recent chemother-
apy, organ transplant, or dialysis treatment within the last
month [13]. The Institutional Review Board at each study
site approved the protocol and participants gave written,
informed consent. For this analysis, participants with
known self-reported cardiovascular disease, peripheral vas-
cular disease, or heart failure were excluded.
Kidney function was measured using cystatin-based
eGFR (eGFRcys) and creatinine-based eGFR using the
MDRD equation (eGFRcr). Compared to creatinine, cys-
tatin has been shown to be a better marker of kidney
function at higher eGFR [14], and cystatin has a stronger
association with cardiovascular outcomes than creatinine-
based eGFR (eGFRcr) [15,16]. In CRIC, eGFRcys has a
wider distribution of values than eGFRcr because enroll-
ment was based upon a fixed range of eGFR [17]. Samples
for cystatin were processed using a Siemens BNII nephel-
ometer at the CRIC central laboratory, with a coefficient
of variation (CV) of 4.9%. Values were corrected for drift
over time by standardization to calibrator lot 51 and re-
agent lot 40. Cystatin-c based eGFR was calculated bythe CKD-EPI equation [18], and eGFR was categorized
as < 30, 30–44, 45–59, and ≥ 60 ml/min/1.73 m2. Urine
samples were collected for spot albumin-creatinine ra-
tios (ACR), and ACR was categorized as < 30, 30–299,
300–999, and ≥ 1000 mg/g.
Information on demographics and clinical history was
obtained by self-report on questionnaires administered
at the baseline visit. Diabetes was defined as documented
medical history, current or previous use of diabetic medi-
cations, or elevated fasting blood glucose. Blood pressure
was averaged over three measurements performed in a
standardized fashion in a seated position at rest using a
calibrated sphygmomanometer. Echocardiograms were
performed at one year after enrollment and were read
at the core echocardiography laboratory (University of
Pennsylvania) using guidelines of the American Society
of Echocardiography [19]. Left ventricular mass index
was derived by the area-length method, indexed to
height2.7 [19]. Hs-TnT was measured at Rapid Response
Laboratories, University of Maryland Medical Center
with the Roche Elecsys immunoassay (Roche Diagnos-
tics, Indianapolis, Indiana), which has an analytical
range of 3 to 10,000 ng/L, and a coefficient of variation
of 9% at 13.5 ng/L (the 99th percentile in a healthy ref-
erence group) [20].Statistical analysis
Of 2505 subjects without CVD, 2464 had hs-TnT mea-
surements, and of these 474 (19%) were undetectable (< 3
pg/ml). We first categorized hs-TnT as undetectable (< 3
pg/ml), Tertile 1 (3–8.6 pg/ml), Tertile II (8.7-17 pg/ml),
and Tertile III (17–739 pg/ml). We compared characteris-
tics of participants in these four categories using ANOVA
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squared tests for categorical variables.
We next performed multivariable regression analysis
in order to identify factors with independent associations
with hs-TnT. Because such a large proportion of hs-TnT
values were undetectable, we used tobit regression, which is
designed to handle left-censored values. Undetectable
values were assigned the level 1.5 pg/ml. Because hs-TnT is
right-skewed, the outcome was log-transformed for analysis.
Coefficients were then exponentiated to yield the estimated
multiplicative increase attributable to each factor; e.g., an
exponentiated coefficient of 1.3 represents a 30% higher
hs-TnT in the exposed compared with the unexposed.
Initially, the regression model included all candidateTable 1 Characteristics of chronic renal insufficiency cohort p
Undetectable Tertile
(hs-TnT < 3) (3.00-8.6
(n=474) (n=666
Hs-TnT (pg/ml)* 1.5 (1.5-1.5) 5.7 (4.6-7
Age 51.5 (11.8) 55.7 (11.
Female 75.5 53.8
Race
Non-Hispanic White 53.2 49.9





Current smoking 13.1 10.4
SBP (mmHg) † 124.1 (16.9) 128.3 (17
DBP (mmHg) ‡ 75.1 (12.1) 75.5 (11.
BMI (kg/m2) § 30.6 (8.5) 31.2 (7.9
HDL (mg/dL) || 54.1 (17.7) 50.9 (15.
LDL (mg/dL) 108.9 (30.4) 107.7 (34
Triglycerides (mg/dL) 144.2 (114.1) 155.2 (115
Total cholesterol (mg/dL) 193.7 (37.6) 192.3 (41
Serum albumin (g/dL) 4.2 (0.4) 4.1 (0.4
hsCRP (mg/L) # 4.9 (8.3) 4.9 (8.8
Hemoglobin (g/dL) 13.2 (1.5) 13.2 (1.8
Phosphate (mg/dL) 3.6 (0.6) 3.6 (0.5
FGF-23 (RU/ml)** 104.7 (73.8-160.2) 114.6 (81.3-1
eGFRcys †† (ml/min/1.73m2) 66.1 (22.7) 55.9 (19.
ACR (μg/mg) ψ 11.2 (5.0-86.9) 21.3 (5.4-20
LV mass (g/m2.7) Ω 43.8 (10.2) 46.1 (10.
Ejection fraction (%) 55.7 (6.3) 55.9 (6.4
Mean (SD) or median (IQR) are reported for continuous variables and percentage fo
tests for continuous variables and Chi-squared tests for categorical variables. * High
Body mass index. || High density lipoprotein. Low density lipoprotein. # High sensit
estimated glomerular filtration rate. ψ Albumin to creatinine ratio. Ω Left ventriculacovariates with p-value < 0.05 by univariate analysis.
Model 1 was built using backwards stepwise selection
until only covariates significant at p < 0.05 remained.
Model 2 was built by adding LV mass and ejection frac-
tion to Model 1. All analyses were performed using
STATA 11 (StataCorp LP, College Station, TX).
Results
In this subgroup of CRIC study participants without CVD,
hs-TnT was detectable in 81% of subjects, and median
(IQR) of hs-TnT was 9.4 pg/ml (4.3-18.3) (Figure 1). In-
creased age, male gender, black race and Hispanic ethni-
city were associated with higher TnT, as were diabetes
and hypertension. Subjects with higher hs-TnT had lowerarticipants with high sensitivity troponin t measurements
I Tertile II Tertile III P
3) (8.67-17.03) (17.05-738.7)
) (n=661) (n=663)
.1) 11.9 (10.1-14.2) 30.0 (21.4-45.3) < 0.001
8) 60.3 (10.7) 59.2 (11.1) < 0.001






45.1 68.3 < 0.001
91.4 94.7 < 0.001
11.8 11.0 0.526
.3) 132.9 (19.5) 140.5 (20.9) < 0.001
9) 74.3 (12.0) 76.8 (11.8) 0.010
) 32.3 (8.1) 32.5 (7.5) < 0.001
2) 49.1 (16.2) 46.4 (15.4) < 0.001
.1) 102.4 (34.7) 98.7 (36.3) < 0.001
.1) 149.3 (91.1) 161.3 (108.0) < 0.001
.4) 184.3 (44.8) 182.0 (45.6) < 0.001
) 4.1 (0.4) 3.9 (0.5) < 0.001
) 5.4 (8.7) 5.7 (9.8) 0.015
) 13.0 (1.8) 12.2 (1.8) < 0.001
) 3.6 (0.6) 3.9 (0.7) < 0.001
82.5) 137.4 (93.3-208.8) 171.7 (113.9-293.0) < 0.001
7) 49.5 (16.3) 40.9 (16.2) < 0.001
1.7) 30.5 (7.9-279.7) 289.7 (31.4-1393.2) < 0.001
4) 50.3 (12.8) 55.4 (13.8) < 0.001
) 55.8 (7.4) 54.3 (7.3) < 0.001
r categorical variables. P values are obtained using ANOVA or Kruskal-Wallis
sensitivity troponin T. † Systolic blood pressure. ‡ Diastolic blood pressure. §
ivity c-reactive protein. ** Fibroblast growth factor 23. †† Cystatin-based
r.
Table 2 Associations between renal factors and high sensitivity troponin t
Unadjusted Model 1 Model 2
N* Tobit ratio (95% CI) P Tobit ratio (95% CI) P Tobit ratio (95% CI) P
eGFRcys* (ml/min/1.73m2)
≥ 60 757 Reference - Reference Reference -
45-59 684 2.11 (1.86-2.41) < 0.001 1.51 (1.35-1.69) < 0.001 1.50 (1.34-1.67) < 0.001
30-44 705 3.02 (2.66-3.44) < 0.001 1.97 (1.74-2.22) < 0.001 1.96 (1.74-2.21) < 0.001
< 30 311 5.27 (4.47-6.21) < 0.001 2.90 (2.47-3.41) < 0.001 2.83 (2.41-3.33) < 0.001
ACR (μg/mg) †
< 30 1115 Reference - Reference Reference -
30-299 582 1.58 (1.39-1.80) < 0.001 1.08 (0.98-1.20) 0.130 1.06 (0.96-1.19) 0.214
300-999 338 1.94 (1.66-2.28) < 0.001 1.09 (0.96-1.25) 0.191 1.08 (0.95-1.23) 0.238
≥ 1000 325 3.61 (3.08-4.23) < 0.001 1.56 (1.35-1.81) < 0.001 1.53 (1.32-1.77) < 0.001
Phosphate (mg/dL)
< 3 265 Reference - Reference Reference -
3-3.9 1427 1.08 (0.90-1.28) 0.419 1.02 (0.90-1.17) 0.739 1.02 (0.90-1.17) 0.711
4-4.9 646 1.59 (1.31-1.93) < 0.001 1.06 (0.91-1.23) 0.445 1.06 (0.92-1.24) 0.412
≥ 5 81 3.51 (2.52-4.90) < 0.001 1.35 (1.04-1.76) 0.023 1.39 (1.08-1.81) 0.012
FGF-23 ‡
Quartile I 606 Reference Reference Reference
Quartile II 606 1.45 (1.25-1.68) < 0.001 1.07 (0.96-1.20) 0.230 1.08 (0.96-1.21) 0.206
Quartile III 606 2.11 (1.82-2.45) < 0.001 1.20 (1.06-1.35) 0.004 1.17 (1.04-1.33) 0.011
Quartile IV 606 2.62 (2.26-3.04) < 0.001 1.22 (1.06-1.40) 0.004 1.17 (1.02-1.34) 0.021
*N’s are # observations among participants with TnT measurements, with 7 observation excluded.
Model 1 adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin (per SD), eGFR_CysC, ACR, and phosphate and FGF-23. Model 2 adjusted for:
Model 1 + LV mass, ejection fraction.
eGFRcys=cystatin-based estimated glomerular filtration rate. † albumin to creatinine ratio. ‡ fibroblast growth factor 23.
Figure 2 Joint associations of categories of estimated
glomerular filtration rate and albumin to creatinine ratio with
high sensitivity troponin t in adjusted tobit regression
analyses. Legend: After multivariate adjustment, lower eGFR and
higher albuminuria were associated with higher levels of hs-TnT.
Final Tobit model adjusted for: age (per SD), female, race, diabetes,
SBP categories, albumin (per SD), LV mass, ejection fraction, eGFRcys,
ACR, and phosphate and FGF-23 (per SD). SD: standard deviation.
SBP: systolic blood pressure. LV: left ventricular. eGFRcys: cystatin-
based estimated glomerular filtration rate. ACR: albumin to
creatinine ratio. FGF-23: fibroblast growth factor 23.
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higher phosphorus, higher FGF-23, lower eGFRcys and
higher ACR (Table 1).
After multivariate adjustment, the strongest renal pre-
dictor of hs-TnT was eGFRcys. All eGFRcys categories
below the referent group of > 60ml/min/1.73m2 were asso-
ciated with incrementally higher hs-TnT. Subjects with
eGFRcys < 30 ml/min/1.73m2 had almost a 3-fold higher
hs-TnT than the referent group with eGFRcys > 60 ml/
min/1.73m2. ACR did not show a linear association with
hs-TnT; only those subjects with ACR ≥ 1000 mg/g had
higher hs-TnTcompared to those with ACR < 30 mg/g. As-
sociations of phosphate and FGF-23 with hs-TnT were sig-
nificantly attenuated by adjustment, and hemoglobin lost
significance with adjustment (compared to referent cat-
egory of hemoglobin > 14, hemoglobin <=11 had 16%
higher hs-TnT, p=0.07) (Table 2). We found an additive ef-
fect between eGFRcys and ACR when we further catego-
rized subjects by both of these factors. After multivariate
adjustment, those in the lowest eGFR/highest ACR cat-
egory (eGFRcys< 30 ml/min/1.73m2 and ACR ≥ 1000) had
more than a 4-fold increase in hs-TnT compared to the
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30) (Figure 2).
Several non-renal covariates remained strong predic-
tors of hs-TnT after multivariable adjustment. Increased
age was associated with higher hs-TnT, and hs-TnT was
substantially lower in women compared to men. Com-
pared to non-Hispanic whites, non-Hispanic blacks had
significantly higher hs-TnT; although Hispanic partici-
pants had higher TnT levels, the association was not sig-
nificant. Higher LV mass index was associated with higher
hs-TnT across all categories of LV mass index; lower ejec-
tion fraction was associated with higher hs-TnT mainly in
the lowest category (≤ 35%). Diabetes, elevated SBP and
lower serum albumin were independently associated with
higher hs-TnT (Table 3). After adjustment, the following
markers were not associated with higher hs-TnT (BTable 3 Associations between non-renal factors and high sen
Unadjusted
N* Tobit ratio (95% CI) P
Age (per SD) 2,457 1.39 (1.32-1.46) < 0.001
Female 1,190 0.41 (0.37-0.46) < 0.001
Race
Non-Hisp white 1,075 Reference -
Non-Hisp Black 946 1.51 (1.34-1.70) < 0.001
Hispanic 330 2.09 (1.77-2.47) < 0.001
Other 106 1.10 (0.84-1.44) 0.492
Diabetes 1,009 2.96 (2.68-3.28) < 0.001
Albumin (per SD) 2,437 0.72 (0.68-0.76) < 0.001
SBP (mmHg)*
< 120 408 Reference -
120-129 324 1.32 (1.09-1.61) 0.005
130-139 321 1.69 (1.39-2.05) < 0.001
140-149 194 2.03 (1.62-2.55) < 0.001
150-159 131 2.71 (2.09-3.51) < 0.001
≥ 160 163 3.36 (2.64-4.27) < 0.001
LV mass (g/m2.7) †
< 40 474 Reference -
40-59 1,165 1.94 (1.68-2.24) < 0.001
60-79 284 3.89 (3.20-4.72) < 0.001
80-99 41 3.77 (2.49-5.72) < 0.001
≥ 100 10 4.85 (2.15-10.95) < 0.001
Ejection fraction (%)
> 50 1,845 Reference -
46-50 197 1.12 (0.92-1.38) 0.253
36-45 130 1.33 (1.04-1.69) 0.023
≤ 35 22 1.93 (1.09-3.41) 0.024
*N’s are # observations among participants with TnT measurements, with 7 observa
Model 1 adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin
Model 1 + LV Mass, ejection fraction. * Systolic blood pressure. † Left ventricular.coefficient per SD (95% CI)): hsCRP 0.98 (0.94-1.02),
p=0.386; LDL 1.01 (0.97-1.06), p=0.510; HDL 1.04 (0.99-
1.09), p=0.126; triglycerides 0.99 (0.95-1.03), p=0.597. The
associations of renal and non-renal covariates were con-
sistent across categories of renal function. Substitution of
eGFRcr for eGFRcys did not change our findings.
Discussion
In this study of participants without CVD selected from
the CRIC cohort, over 80% had detectable levels of hs-
TnT. Lower eGFR, higher LV mass, increased age, male
gender, black race, diabetes and higher blood pressure were
independently associated with higher hs-TnT. Interpreting
these associations may help us understand which subjects
with CKD are most susceptible to developing coronary dis-
ease or heart failure.sitivity troponin t
Model 1 Model 2
Tobit ratio (95% CI) P Tobit ratio (95% CI) P
1.31 (1.25-1.37) < 0.001 1.31 (1.25-1.37) < 0.001
0.38 (0.35-0.41) < 0.001 0.39 (0.36-0.42) < 0.001
Reference - Reference -
1.31 (1.20-1.43) < 0.001 1.26 (1.16-1.38) < 0.001
1.06 (0.93-1.21) 0.398 1.02 (0.89-1.16) 0.768
1.03 (0.84-1.25) 0.807 1.02 (0.84-1.24) 0.854
1.87 (1.71-2.04) < 0.001 1.84 (1.69-2.00) < 0.001
0.92 (0.88-0.96) 0.001 0.93 (0.89-0.98) 0.003
Reference - Reference -
1.03 (0.89-1.19) 0.678 1.03 (0.89-1.19) 0.706
1.14 (0.98-1.32) 0.081 1.12 (0.97-1.29) 0.139
1.24 (1.05-1.47) 0.014 1.22 (1.03-1.44) 0.023
1.44 (1.19-1.76) < 0.001 1.38 (1.14-1.69) 0.001
1.35 (1.12-1.63) 0.001 1.27 (1.06-1.53) 0.011
Reference -
1.17 (1.05-1.30) 0.006








(per SD), eGFR_CysC, ACR, and phosphate and FGF-23. Model 2 adjusted for:
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parable to subjects with stable coronary artery disease
(5–6 pg/ml [21]) and heart failure (13–17 pg/ml [22]).
This degree of chronic, low-level troponin release has
been attributed to various mechanisms in addition to
macrovascular atherosclerotic disease. Left ventricular
hypertrophy (LVH) is common in this population, and is
associated with higher levels of hs-TnT [11]. Chronic
kidney disease may lead to myocardial injury via endo-
thelial dysfunction and microvascular disease caused by
elevated levels of asymmetric dimethylarginine (ADMA)
[23] or mediators of oxidative stress [24]. Alternatively,
the association between lower eGFR and higher TnT
could be in part due to reduced renal clearance of tropo-
nin T. Troponin T fragments small enough to be cleared
by the kidneys have been found in serum of patients
with ESRD [25]. However, we also show that LV mass is
associated with hs-TnT independently of eGFR; further-
more, 5% of persons with eGFR< 30 and 10% with eGFR
between 30–45 had undetectable hs-TnT, demonstrating
that impaired clearance is unlikely to be solely respon-
sible for detectable levels of hs-TnT.
Similar to the Dallas Heart Study in which hs-TnT
was studied in a community-based cohort [4] we found
that older age, male gender, black race and diabetes were
independently associated with elevated hs-TnT. While it
seems intuitive that older age and diabetes would be as-
sociated with microvascular injury and thus lead to
higher hs-TnT, the explanation for male gender and
black race is less obvious. Male gender and black race
are associated with higher LV mass index [26-28], but in
our study these associations persisted after adjustment
for LV mass index. African Americans have been found
to have a higher risk of endothelial dysfunction [29,30],
and this may explain the higher levels of hs-TnT among
them in our cohort.
Prior studies have shown FGF-23 to have strong, inde-
pendent associations with structural cardiovascular dis-
ease including LVH [31], coronary artery disease [32],
and carotid intima-media thickness [33]; cardiovascular
events [34]; and overall mortality [13,35] in cohorts with
prevalent CVD and all stages of CKD [13]. One role of
FGF-23 in cardiovascular disease is via induction of left
ventricular hypertrophy; FGF-23 injected into mice at
concentrations of 800 RU/ml resulted in LVH [36]. In
addition, the growth factor was associated with myocar-
dial injury (hs-TnT) in a CKD cohort, an association
that was only mildly attenuated by adjustment for LVH
[37]. In contrast, we observed only a weak association
of FGF-23 with hs-TnT levels with or without adjust-
ment for LV mass index. The fact that we excluded
CRIC participants with history of CVD may account
for these differences. While FGF-23 does not appear
to be a predominant factor for subclinical myocardialinjury in CRIC subjects without CVD, it may yet prove
crucial in the development of heart failure in this co-
hort via induction of LVH.
Strengths of our study include the large study cohort,
broad range of eGFRcys and ethnic diversity represented
by CRIC. The high percentage of participants with detect-
able hs-TnT increased our power to detect cross-sectional
associations. There are also several important limitations.
Subjects with known cardiovascular disease were excluded
based on history, not left heart catheterization; some sub-
jects with undetected coronary artery disease may have
been included. Since our analysis is cross-sectional, we
cannot assume a causal relationship between factors asso-
ciated with hs-TnT and hs-TnT or incident CVD. We can-
not separate the relative importance of hs-TnT production
vs. clearance as determinants of serum concentrations.
Conclusions
We conclude that in the absence of CVD, the most im-
portant renal predictor of higher hs-TnT in the CRIC
cohort is lower eGFRcys. Non-renal predictors include
age, male gender, black race, diabetes, and higher systolic
blood pressure. Further studies will evaluate whether hs-
TnT is associated with adverse outcomes in CRIC.
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